Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2)
NCT05011760Phase 1Recruiting
- Start
- Jan 2021
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adenosine-5′-monophosphate in cocaine use disorder (CUD). Primary endpoint: DELTA binding potential relative to non displaceable uptake. Started Jan 2021; status: recruiting.
02
Drugs
adenosine-5′-monophosphate
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT05011760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011760.